Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Net Cash Flow (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Net Cash Flow data on record, last reported at -$11.8 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 16.37% year-over-year to -$11.8 million; the TTM value through Sep 2025 reached -$1.8 million, up 96.04%, while the annual FY2024 figure was -$3.9 million, 619.85% down from the prior year.
  • Net Cash Flow reached -$11.8 million in Q3 2025 per CRVS's latest filing, down from $9.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $12.4 million in Q3 2023 and bottomed at -$32.0 million in Q1 2022.
  • Average Net Cash Flow over 4 years is -$6.1 million, with a median of -$3.9 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: soared 420.06% in 2023, then crashed 1051.55% in 2024.
  • A 4-year view of Net Cash Flow shows it stood at -$11.4 million in 2022, then skyrocketed by 34.51% to -$7.5 million in 2023, then skyrocketed by 154.24% to $4.1 million in 2024, then crashed by 391.23% to -$11.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$11.8 million in Q3 2025, $9.7 million in Q2 2025, and -$3.7 million in Q1 2025.